PMID: 25745736Mar 10, 2015Paper

Stem cell collection considerations for AL amyloidosis

Connecticut Medicine
Eric A Gehrie, Garrett S Booth

Abstract

Amyloidosis is a progressive disease that traditionally is associated with poor clinical outcomes. Recent advances in amyloidosis treatment may allow for more patients tobe considered for autologous stem cell transplantation. In this report, we review a case of autologous peripheral blood stem cell transplantation in a patient with systemic amyloidosis and review special considerations in peripheral blood stem cell collection in such patients. We conclude that it may be reasonable to consider substituting heparin for some of the citrate used in peripheral blood stem cell collection procedures performed on patients with cardiac amyloidosis, so long as there are no contraindications to heparin exposure.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.

Related Papers

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
J B PerzT J Dengler
BMJ : British Medical Journal
R Hall, Philip N Hawkins
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis
R RyšaváI Špička
© 2022 Meta ULC. All rights reserved